Edwards Lifesciences Co. (NYSE:EW) Shares Bought by Livforsakringsbolaget Skandia Omsesidigt

Livforsakringsbolaget Skandia Omsesidigt grew its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 131.7% in the 4th quarter, HoldingsChannel.com reports. The fund owned 17,237 shares of the medical research company’s stock after acquiring an additional 9,797 shares during the period. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Edwards Lifesciences were worth $1,314,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in EW. Vanguard Group Inc. grew its stake in shares of Edwards Lifesciences by 0.6% in the third quarter. Vanguard Group Inc. now owns 51,633,416 shares of the medical research company’s stock valued at $3,577,163,000 after buying an additional 325,808 shares in the last quarter. Alliancebernstein L.P. lifted its holdings in shares of Edwards Lifesciences by 0.3% in the 2nd quarter. Alliancebernstein L.P. now owns 20,512,235 shares of the medical research company’s stock worth $1,934,919,000 after purchasing an additional 66,763 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Edwards Lifesciences by 9.2% in the 3rd quarter. Wellington Management Group LLP now owns 16,434,401 shares of the medical research company’s stock worth $1,138,575,000 after purchasing an additional 1,390,427 shares during the last quarter. Moneta Group Investment Advisors LLC lifted its holdings in shares of Edwards Lifesciences by 104,971.3% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 15,399,249 shares of the medical research company’s stock worth $1,148,938,000 after purchasing an additional 15,384,593 shares during the last quarter. Finally, Brown Advisory Inc. lifted its holdings in shares of Edwards Lifesciences by 5.7% in the 3rd quarter. Brown Advisory Inc. now owns 15,133,146 shares of the medical research company’s stock worth $1,048,424,000 after purchasing an additional 818,849 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $86.27 on Thursday. The company has a market capitalization of $51.93 billion, a price-to-earnings ratio of 37.93, a P/E/G ratio of 4.46 and a beta of 1.05. Edwards Lifesciences Co. has a 1-year low of $60.57 and a 1-year high of $96.12. The company has a current ratio of 3.38, a quick ratio of 2.40 and a debt-to-equity ratio of 0.09. The stock’s fifty day simple moving average is $90.12 and its 200-day simple moving average is $78.14.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, February 6th. The medical research company reported $0.64 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.64. The firm had revenue of $1.53 billion during the quarter, compared to analysts’ expectations of $1.50 billion. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. The business’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same quarter last year, the firm earned $0.64 earnings per share. On average, sell-side analysts predict that Edwards Lifesciences Co. will post 2.76 earnings per share for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, Director Michael A. Mussallem sold 29,350 shares of the business’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $86.67, for a total value of $2,543,764.50. Following the completion of the sale, the director now owns 4,486 shares of the company’s stock, valued at $388,801.62. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Edwards Lifesciences news, VP Jean-Luc M. Lemercier sold 14,400 shares of the company’s stock in a transaction on Monday, April 8th. The stock was sold at an average price of $92.32, for a total value of $1,329,408.00. Following the sale, the vice president now directly owns 173,849 shares in the company, valued at $16,049,739.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Michael A. Mussallem sold 29,350 shares of the stock in a transaction on Monday, March 4th. The stock was sold at an average price of $86.67, for a total value of $2,543,764.50. Following the transaction, the director now owns 4,486 shares of the company’s stock, valued at $388,801.62. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 194,004 shares of company stock valued at $17,166,254. Insiders own 1.29% of the company’s stock.

Wall Street Analyst Weigh In

EW has been the topic of several recent research reports. Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating in a report on Thursday, March 7th. Stifel Nicolaus lifted their target price on Edwards Lifesciences from $70.00 to $83.00 and gave the company a “hold” rating in a research note on Wednesday, February 7th. Morgan Stanley lifted their target price on Edwards Lifesciences from $95.00 to $103.00 and gave the company an “overweight” rating in a research note on Thursday, March 21st. Mizuho lifted their target price on Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a research note on Thursday, April 11th. Finally, Citigroup lifted their target price on Edwards Lifesciences from $90.00 to $98.00 and gave the company a “neutral” rating in a research note on Wednesday, April 3rd. One research analyst has rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $91.73.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.